Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $26.24 (market cap $4.49B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.02. Which is the better fit depends on your goals.
| ACAD | VWO | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $61.24 |
52-Week Low | $20.06 | $49.54 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
VWO (Vanguard FTSE Emerging Markets ETF) trades at $60.07, up 1.74% on the day, with a bullish technical signal from moving averages. The ETF maintains a low 0.06% expense ratio and a 2.4% dividend yield, positioning it as a cost-efficient emerging markets vehicle. Recent news highlights performance comparisons with competing funds and the impact of South Korea's exclusion from its index, which has contributed to underperformance relative to some peers year-to-date.
The outlook for VWO hinges on broad emerging market growth and its low-cost advantage, but faces risks from geopolitical tensions, index methodology excluding South Korea, and potential underperformance versus developed market funds. The ETF offers diversification but may lag during periods of US market strength or when specific excluded markets outperform.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
